In this context, Koh et al., [31] in a study of 157 HR+ HER2-BC patients treated with neoadjuvant chemotherapy (mean follow-up of 21 months after surgery), showed that a NLR higher than 2.25 was associated with shorter recurrence-free and overall survivals. The gene discussed is ERBB2; the disease is breast cancer.